Clinical Inquiries

What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events?

Author and Disclosure Information

 

References

Aspirin carries risk of GI hemorrhage, but not hemorrhagic stroke

A companion 2016 systematic review of 16 RCTs, cohort studies, and meta-analyses evaluated the risk of serious bleeding in patients using low-dose aspirin for primary prevention of either CVD or cancer.3 The review (number of patients not reported) found that estimated excess bleeding events differed substantially depending on varying sources for baseline bleeding rates in aspirin nonusers.

The most conservative comparison yielded an NNH of 72 over 10 years of therapy (1.39 excess major GI bleeding events per 1000 person-years, 95% CI, 0.70-2.28). Comparison with other baseline bleeding rates in trial data yielded less risk of harm, with an NNH of 357 over 10 years (0.28 excess major GI bleeding events per 1000 person-years; 95% CI, 0.14-0.46). Excess risk for hemorrhagic stroke was not statistically significant (0.32 excess events per 1000 person-years; 95% CI, −0.05 to 0.82).

RECOMMENDATIONS

The US Preventive Services Task Force gives a Grade B recommendation (recommended, based on moderate to substantial benefit) to the use of aspirin to prevent CVD among adults ages 50 to 59 years with an ASCVD risk ≥10% who don’t have increased bleeding risk and are capable of 10 years of pharmacologic adherence with a similar expected longevity.4 The Task Force assigns a Grade C recommendation (individual and professional choice) to patients 60 to 69 years of age with the same constellation of risk factors and health status. Insufficient evidence was available to make recommendations for other age cohorts.

The American College of Chest Physicians recommends 75 to 100 mg of aspirin daily for adults 50 years or older who have moderate to high CV risk, defined as ≥10%.5

A working group of the European Society of Cardiology (ESC) released a statement in 2014 recommending aspirin for primary prevention in adults with a CV risk ≥20% and no risk factors for bleeding. For patients with a CVD risk between 10% and 20%, the ESC recommends deferring to patient preference.6

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Family Medicine
MDedge Daily News: Avoid warfarin’s polypharmacy perils
MDedge Family Medicine
Top hospital heart failure performance translates to longer survival
MDedge Family Medicine
Statin use is uniformly low in adults with dyslipidemia disorders
MDedge Family Medicine
‘If this is an emergency, call 911’
MDedge Family Medicine
Major message: Most heart failure is preventable
MDedge Family Medicine
High-dose oral ibuprofen most effective for PDA closure
MDedge Family Medicine
VIDEO: Women living with HIV have more myocardial steatosis, reduced diastolic function
MDedge Family Medicine
MDedge Daily News: Why most heart failure may be preventable
MDedge Family Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Family Medicine